Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Squamous Cell Carcinoma of Head and Neck 4 Lung Neoplasms 3 Melanoma 2 Head and Neck Neoplasms 2 Carcinoma, Hepatocellular 2 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Squamous Intraepithelial Lesions 1 Skin Neoplasms 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Rectal Neoplasms 1 Prostate Adenocarcinoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Papillomavirus Infections 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms 1 Neoplasm, Residual 1 Nasopharyngeal Carcinoma 1 Liver Diseases 1 Liposarcoma 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Breast Neoplasms 1

Interventions

Doxorubicin 25 Radiotherapy 16 Ifosfamide 14 Trabectedin 10 pazopanib 6 ribociclib 5 pembrolizumab 5 Specimen Handling 5 Magnetic Resonance Spectroscopy 5 Gemcitabine 5 Biopsy 5 palbociclib 4 Radiation 4 Docetaxel 4 Chemotherapy, Adjuvant 4 selinexor 3 liposomal doxorubicin 3 eribulin 3 abemaciclib 3 X-Rays 3 Vincristine 3 Neoadjuvant Therapy 3 Imatinib Mesylate 3 Filgrastim 3 Etoposide 3 Cyclophosphamide 3 toripalimab 2 temsirolimus 2 romidepsin 2 pegfilgrastim 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Liposarcoma × Adjuvants, Pharmaceutic × Clear all

NCT06116578 2025-12-01

NeoSarc

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn

Liposarcoma, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡